UK agrees joint investment with Valneva to boost vaccine production


© Reuters. FILE PHOTO: A woman holds a small bottle labeled with a “Vaccine COVID-19” sticker and a medical syringe in this illustration

LONDON (Reuters) – Britain has agreed a multi-million pound joint investment with French speciality vaccines company Valneva (PA:) to upgrade a manufacturing facility and increase production capacity for a possible COVID-19 vaccine.

Britain said in July it had agreed in principle to buy 60 million doses of a Valneva vaccine, with an option to purchase 40 million more if it proved safe, effective and suitable.

The government did not disclose the exact size of the investment, and had previously said it was in talks about providing funding for the facility in Livingston, Scotland.

Valneva has previously said it is aiming for clinical trials of its vaccine to start in November or December this year.

The upgraded facility could potentially supply 100 million vaccine doses to Britain and internationally, the government said in a statement.

Governments around the world are locked in a race to secure a vaccine that could help their citizens, and economies, to recover from the pandemic.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

READ  US producer prices rose slightly in June, while the cost of goods declined

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.





READ SOURCE

LEAVE A REPLY

Please enter your comment!
Please enter your name here